Studies Show CAR-T Therapy Carries Extremely Low Secondary Cancer Risk

Published on Spencer Knight via LinkedIn

Concerns about secondary cancers from CAR-T therapy may be overstated, according to new data. A Memorial Sloan Kettering study of over 5,500 patients found no significant increase in secondary cancer risk compared to standard treatments. Only 0.09% of cases were T-cell related. A second study from France showed similar results, with just one malignancy among more than 3,000 patients treated.

Spencer Knight points out that longer lifespans and prior therapies may skew cancer statistics more than CAR-T itself. He advocates removing unnecessary regulatory blocks, especially with modern CRISPR-edited T cells equipped with built-in safety switches. The cure-to-risk ratio remains overwhelmingly in favor of treatment.

Read the full post on LinkedIn:

👉 Spencer Knight: Secondary cancer risks from CAR-T therapy are a concern… but may be overstated

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.